Pharmaceutical development of composition of effervescent tablets with acetylsalicylic acid, paracetamol, and ascorbic acid Authors: Oksana Panysheva Published: 2026 ABSTRACT AbstractThis study aims to develop and optimize a stable composition of effervescent tablets containing acetylsalicylic acid (300 mg), paracetamol (200 mg), and ascorbic acid (300 mg) for the Ukrainian pharmaceutical market. A systematic pharmaceutical development approach was employed, utilizing dispersion and regression analysis to evaluate the impact of various functional groups of excipients on twelve critical quality indicators. The research included a comprehensive assessment of the tableting blend's pharmaco-technological properties (bulk/tapped density, Carr's index, flowability, and angle of repose) and the finished tablets' quality (pressing process, appearance, mass uniformity, hardness, friability, and disintegration). Organoleptic attributes of the resulting solution, including transparency, odor, and taste, were also evaluated. The initial screening phase identified the most effective types of fillers, disintegrants, and lubricants for direct compression. Experimental data scientifically established the optimal stoichiometric ratio between anhydrous citric acid and sodium bicarbonate as 1:1.312. Subsequent optimization using a utility function and regression analysis allowed for the selection of the best glidants, sweeteners, and flavorings. The interaction between the quantities of a co-processed binder and a sorbitol-based filler was proved to be critical for achieving the required tablet hardness and rapid disintegration. The finalized composition, containing an optimized matrix of anhydrous citric acid, sodium bicarbonate, lactose, polyvinylpyrrolidone, crospovidone, sorbitol, sodium saccharin, lemon flavoring, and sodium stearyl fumarate, successfully met all pharmacopoeial requirements and exceeded the criteria of the Quality Target Product Profile. Long-term stability studies confirmed a 24-month shelf life in aluminum-polymer packaging. The study resulted in a scientifically validated composition that provides a fast-acting, consumer-friendly, and cost-effective domestic alternative to imported analgesic and antipyretic combinations, significantly enhancing patient compliance and accessibility within the local market.Keywords: Pharmaceutical development, Effervescent tablets, Quality by design, Dispersion analysis, Regression analysis Introduction The evolution of oral dosage forms has consistently aimed to balance patient convenience with optimal pharmacokinetic performance. According to the Food and Drug Administration and the European Pharmacopoeia, effervescent tablets are defined as solid dosage forms designed to dissolve or disperse in water before use, typically containing acidic substances and carbonates that react rapidly to release carbon dioxide [1,2]. This category of pharmaceuticals is experiencing a significant surge in popularity among clinicians and patients due to several biopharmaceutical advantages. The primary benefit is the accelerated release of the active pharmaceutical ingredient (API), bypassing the rate-limiting disintegration step required for conventional tablets [3,4]. This results in faster absorption and an earlier onset of therapeutic action, which is critical for acute conditions such as pain and fever [5,6]. Furthermore, administering the drug in a pre-dissolved state minimizes the localized irritation of the gastrointestinal mucosa, a common drawback of solid acetylsalicylic acid (ASA) [7,8]. From a clinical perspective, effervescent forms enhance patient compliance, particularly in pediatric and geriatric populations where swallowing large tablets (dysphagia) is a major barrier to adherence [4,9]. They also facilitate the conversion of poorly soluble compounds into solution via salt formation and carbon dioxide-induced solubilization, while simultaneously allowing for the correction of unpleasant organoleptic properties through sophisticated flavoring systems [8,10,11]. The manufacturing of effervescent tablets is a sophisticated technological process requiring a complex multicomponent system, typically involving 5 to 15 functional ingredients [12,13]. The core functionality is driven by a gas-forming mixture (acidic and alkaline fractions), which usually constitutes 80%-95% of the total tablet mass [10,13]. While anhydrous citric acid and sodium bicarbonate remain the most common agents, recent advances explore organic acids like fumaric, malic, or tartaric acid to optimize reaction kinetics and the final solution's pH [7,14]. To prevent premature interaction between these highly hygroscopic fractions during storage, the role of stabilizing agents is paramount. High-molecular compounds, such as polyvinylpyrrolidone (Povidone® K25) and various polyethylene glycols (PEGs) (PEG 6000), function as essential binders that also provide a protective barrier against moisture [6,10]. A critical requirement for this technology is the selection of fillers with high water solubility and superior compressibility for direct compression [11,15]. Functional excipients like anhydrous lactose (SuperTab® 22AN), lactose monohydrate (Tablettose® 80), and polyols such as sorbitol (Neosorb® P60W, Parteck® SI400) and mannitol (Perlitol® 300DC) play a dual role as structure-formers and dissolution promoters [[3], [4], [5]]. Specialized fillers, including dextrose (Compri-Zuger®), sugar spheres (Scerinerts® 50), and microcrystalline cellulose micropellets (Cellets® 100), are often utilized to enhance tablet hardness, which is frequently a weak point in effervescent systems [6,11]. To achieve rapid disintegration, the multifunctional co-processed excipient Ludipress® or superdisintegrants like crospovidone (Polyplasdone® XL-10) are vital for accelerating the matrix breakup [10]. Furthermore, technological challenges like blend adhesion to the tablet press necessitate water-soluble lubricants; hence, traditional magnesium stearate is strictly avoided due to its hydrophobicity and soapy taste, replaced by sodium stearyl fumarate or sodium lauryl sulfate to ensure solution transparency [8,10,13]. The fluidity of these hygroscopic blends is further maintained by advanced glidants like Aerosil® 200 or magnesium aluminosilicate (Neuselin® US2), while the organoleptic profile is refined using high-intensity sweeteners like sodium saccharin or aspartame and fruit flavorings (orange, lemon, etc.) [2,9,14]. The therapeutic rationale for this study is rooted in the well-documented clinical synergy of ASA, paracetamol, and ascorbic acid. This triad provides a dual-action analgesic and antipyretic mechanism (acting on both central and peripheral pathways) while supporting the immune system during inflammatory processes [16,17]. Internationally, this combination is a gold standard for treating flu, colds, and migraines, marketed under prestigious brands such as Afebryl® (Belgium, Portugal), Isofebril® vitamine C (France), Gripral + C ratiopharm® (Germany), Neo-Nisidina® C (Italy), and Thomapyrin® mit Ascorbinsäure (Austria, Bulgaria). Despite its global success, this specific therapeutic combination is currently absent from the Ukrainian pharmaceutical market, representing a significant therapeutic gap [12,16]. In this research, this triad was intentionally selected as a “research object of maximum complexity” to investigate the technological boundaries of direct compression [15,18,19]. These three APIs possess vastly different physical properties – varying in solubility, particle morphology, and compressibility – making the achievement of blend homogeneity and stable flow a rigorous test for modern excipient matrices [20]. Developing a domestic product carries substantial socio-economic value, offering a more cost-effective and accessible alternative to imported analogs while simplifying the treatment regimen for local patients [12,21]. By utilizing a Quality by Design (QbD) approach with dispersion and regression analysis, we aim to overcome the inherent instability of ascorbic acid and the hygroscopicity of the effervescent base [14]. Consequently, the objective of this study is to develop a scientifically validated composition and direct compression technology for obtaining stable effervescent tablets containing 300 mg of ASA, 200 mg of paracetamol, and 300 mg of ascorbic acid. The research focuses on ensuring high-quality appearance, solution transparency, and pleasant organoleptic properties while strictly adhering to pharmacopoeial requirements for mass uniformity, mechanical hardness, friability, and rapid disintegration. Materials and methods Materials Powders of ASA, paracetamol, and ascorbic acid were used as active pharmaceutical ingredients (APIs) for the development of effervescent tablets. The study utilized ASA manufactured by Shandong Xihua Pharmaceutical Co. Ltd. (China), paracetamol by Hebei Jiheng (Group) Pharmaceutical Co. Ltd. (China), and ascorbic acid by DSM Nutritional Products (Switzerland). The ASA powder is a white, odorless crystalline powder; however, in a humid environment (e.g., contact with air), it acquires an acetic acid odor. It consists of oval-shaped particles with smooth edges (D10 = 219 μm, D50 = 703 μm, D90 = 1330 μm). The ASA powder is characterized by a bulk density of 0.6667 ± 0.0230 g/ml, tapped density of 0.8571 ± 0.0571 g/ml, Carr's index of 24.84% ± 2.30%, flowability of 7.7 ± 1.5 s/100 g, and an angle of repose of 37.2 ± 2.9°. The paracetamol is a white amorphous powder with elongated particles (D10 = 5.84 μm, D50 = 40.4 μm, and D90 = 208 μm), providing a bulk density of 0.3850 ± 0.0127 g/ml, tapped density of 0.5934 ± 0.0101 g/ml, Carr's index of 54.20% ± 2.48%. The powder exhibits no flowability (0 s/100 g) and has an angle of repose of (11.6 ± 4.6) ° of the powder. The ascorbic acid is a white crystalline powder consisting of cubic crystals (D10 = 72.8 μm, D50 = 265 μm, and D90 = 523 μm). It is characterized by a bulk density of 0.9329 ± 0.0074 g/ml, tapped density of 1.1545 ± 0.0115 g/ml, Carr's index of 23.76% ± 0.23%, flowability of 11.4 ± 0.8 s/100 g, and angle of repose of 38.3 ± 2.7°. One tablet contains 300 mg ASA, 200 mg paracetamol, and 300 mg ascorbic acid. The following excipients were investigated: sodium bicarbonate, anhydrous citric acid, anhydrous lactose (SuperTab® 22AN), lactose monohydrate (Tablettose® 80), sorbitol (Neosorb® P60W and Parteck® SI400), mannitol (Perlitol® 300DC), dextrose (Compri-Zuger® B, M3, and O), sugar spheres (Scerinerts® 50), microcrystalline cellulose micropellets (Cellets® 100), polyvinylpyrrolidone (Povidone® K25), crospovidone (Polyplasdone® XL-10), sodium croscarmellose, and Ludipress® (93% lactose, 3.5% polyvinylpyrrolidone (Kollidon® 30), and 3.5% crospovidone (Kollidon® CL)). Additional components included sodium lauryl sulfate, sodium stearyl fumarate (Pruv®), PEG 6000, colloidal anhydrous silicon dioxide (Aerosil® 200 and Aeroperl® 300), magnesium aluminosilicate (Neuselin® US2), sodium saccharin, aspartame, and flavorings (lemon, orange, lemon-lime). All materials were of pharmaceutical grade. Packaging utilized pharmaceutical-grade blister packages manufactured from aluminum-polymer laminate foils (cold-form foil) and aluminum foil, ensuring superior moisture and light barriers in compliance with current pharmacopoeial standards. Research methodology and experimental design The pharmaceutical development of effervescent tablets containing ASA, paracetamol, and ascorbic acid was conducted according to a systematic multi-stage research plan: 1.Qualitative composition screening:-comprehensive analysis of the excipient profiles in reference marketed products;-evaluation of the influence of excipient nature on the CQAs of the tableting blend, effervescent tablets, and resulting solution using dispersion analysis;-identification and selection of the optimal qualitative matrix (fillers, disintegrants, and lubricants). Qualitative composition screening:-comprehensive analysis of the excipient profiles in reference marketed products;-evaluation of the influence of excipient nature on the CQAs of the tableting blend, effervescent tablets, and resulting solution using dispersion analysis;-identification and selection of the optimal qualitative matrix (fillers, disintegrants, and lubricants). -comprehensive analysis of the excipient profiles in reference marketed products; comprehensive analysis of the excipient profiles in reference marketed products; -evaluation of the influence of excipient nature on the CQAs of the tableting blend, effervescent tablets, and resulting solution using dispersion analysis; evaluation of the influence of excipient nature on the CQAs of the tableting blend, effervescent tablets, and resulting solution using dispersion analysis; -identification and selection of the optimal qualitative matrix (fillers, disintegrants, and lubricants). identification and selection of the optimal qualitative matrix (fillers, disintegrants, and lubricants). 2.Quantitative composition development:-determination of the stoichiometric ratio for the gas-forming mixture (citric acid/sodium bicarbonate);-investigation of the quantitative characteristics of excipients and their interrelationships using regression analysis;-selection of excipient concentrations that ensure superior pharmaco-technological properties. Quantitative composition development:-determination of the stoichiometric ratio for the gas-forming mixture (citric acid/sodium bicarbonate);-investigation of the quantitative characteristics of excipients and their interrelationships using regression analysis;-selection of excipient concentrations that ensure superior pharmaco-technological properties. -determination of the stoichiometric ratio for the gas-forming mixture (citric acid/sodium bicarbonate); determination of the stoichiometric ratio for the gas-forming mixture (citric acid/sodium bicarbonate); -investigation of the quantitative characteristics of excipients and their interrelationships using regression analysis; investigation of the quantitative characteristics of excipients and their interrelationships using regression analysis; -selection of excipient concentrations that ensure superior pharmaco-technological properties. selection of excipient concentrations that ensure superior pharmaco-technological properties. 3.Formulation optimization:-analysis of additional excipients to enhance the technological and organoleptic properties (glidants, sweeteners, and flavorings) via dispersion analysis;-selection of the best functional components using a utility function;-assessment of Aerosil® 200 concentration impact on powder flow and tablet quality;-research of fillers nature;-evaluation of filler-binder correlations using regression analysis. Formulation optimization:-analysis of additional excipients to enhance the technological and organoleptic properties (glidants, sweeteners, and flavorings) via dispersion analysis;-selection of the best functional components using a utility function;-assessment of Aerosil® 200 concentration impact on powder flow and tablet quality;-research of fillers nature;-evaluation of filler-binder correlations using regression analysis. -analysis of additional excipients to enhance the technological and organoleptic properties (glidants, sweeteners, and flavorings) via dispersion analysis; analysis of additional excipients to enhance the technological and organoleptic properties (glidants, sweeteners, and flavorings) via dispersion analysis; -selection of the best functional components using a utility function; selection of the best functional components using a utility function; -assessment of Aerosil® 200 concentration impact on powder flow and tablet quality; assessment of Aerosil® 200 concentration impact on powder flow and tablet quality; -research of fillers nature; research of fillers nature; -evaluation of filler-binder correlations using regression analysis. evaluation of filler-binder correlations using regression analysis. 4.Final formulation and validation:-experimental validation of the optimized composition;-long-term stability testing and final characterization of the dosage form. Final formulation and validation:-experimental validation of the optimized composition;-long-term stability testing and final characterization of the dosage form. -experimental validation of the optimized composition; experimental validation of the optimized composition; -long-term stability testing and final characterization of the dosage form. long-term stability testing and final characterization of the dosage form. The list of excipients for the reference products was compiled from official instructions for use and summary of product characteristics. Statistical planning and data processing, including dispersion and regression analyses, were performed in accordance with established pharmaceutical guidelines [18,19]. Method of dispersion analysis Dispersion analysis was employed to statistically identify the influence of various factors and their interactions on the variability of the studied pharmaceutical features. The initial screening phase for the effervescent tablet formulation utilized a randomized 3х3 Greek-Latin square design. This orthogonal matrix was selected for its high efficiency in multivariable optimization, allowing for the simultaneous evaluation of three independent factors at three levels through only 9 experimental runs. This significantly reduced material consumption compared to the 27 runs required for a full factorial (33) design. To ensure statistical reliability and reproducibility, each experimental run was performed in duplicate (n = 2), and the order of the runs was fully randomized to eliminate systematic bias. The criteria for selecting factor levels were justified by a pre-formulation market analysis of reference products and preliminary compressibility studies. The inherent balance of the design ensured that each factor level appeared exactly once in combination with others, providing an independent estimation of each ingredient's effect and preventing the confounding of variables. Furthermore, the systematic distribution of factors effectively mitigated background noise from environmental fluctuations, such as minor variations in ambient humidity, which is critical for moisture-sensitive effervescent mixtures. Experimental data were subjected to dispersion analysis using STATISTICA® 10.0 (StatSoft Inc., USA) and Microsoft Excel 2019. Factors were considered statistically significant in cases where Fexperimental > Ftabular (p = 0.05). For all significant factors, a ranked series of advantages was constructed to determine their specific influence on the critical pharmaco-technological indicators of the tableting blend, effervescent tablets, and the resulting solution [18,19]. Utility function The utility function was employed to identify the optimal excipients by summing the ordinal numbers of the factor levels within a ranked series of advantages [19]. In this approach, each quality indicator was treated as a Critical Quality Attribute (CQA) with equal statistical weight. This methodology was selected for the screening and optimization phases to ensure a robust balance across all studied parameters, including pharmacopoeial standards (mass uniformity, hardness, friability, and disintegration) and organoleptic properties (taste and odor). The final selection was strictly restricted to formulations that met the predefined mandatory limits for each critical parameter, ensuring that no single quality attribute was compromised during the optimization process. Method of regression analysis Quantitative characteristics of the excipients and the interrelationships between factors were investigated using regression analysis. For this purpose, a randomized symmetric rotatable composite second-order design was employed in two distinct stages. At the initial stage, four quantitative factors were studied using a matrix of 20 experimental runs, which included 4 replicates at the central (basic) level to determine the variance of reproducibility and ensure statistical precision. During the subsequent optimization stage, two quantitative factors were evaluated using a matrix of 10 experimental runs, with 2 replicates at the central level. The sequence of all experiments across both stages was fully randomized to eliminate systematic bias. Regression analysis enabled the development of mathematical models in the form of polynomial equations. The model coefficients, variance, standard error, and statistical significance were calculated using Student's t-test (t5 = 2.571; p = 0.05). Model adequacy was verified via the Fisher criterion (F-test), where F0.05;15;3 = 8.7 for the four-factor quantitative study and F0,1;6;1 = 58.204 for the two-factor composition optimization. Significant coefficients were used to construct the final regression equations. A regression model was considered adequate if the calculated F-value did not exceed the tabular value for the selected significance level (p < 0.05 or p < 0.01). To assess factor interactions, graphical univariate dependencies were constructed by stabilizing other factors at a constant level. Furthermore, contour plots were generated in the plane of intersection of two factors to visually identify a compromise solution for the optimization problem. To determine the optimal excipient ratios, regression equations were transformed into canonical expressions. Provided that bii>0 and |bi|-∑|bij|>2|bii|, the value + 1 was entered into the model for xi if bі was positive. The coordinates of the intersection of the lines derived from the transformed equations correspond to the quantities of excipients providing the optimal quality indicators [18,19]. Tablet preparation The effervescent tablets, containing 300 mg of ASA, 200 mg of paracetamol, and 300 mg of ascorbic acid, were manufactured using the direct compression method. Accurate weighing of all components was ensured using an electronic balance PB8001-S (Mettler Toledo, Switzerland). All ingredients were blended in a specific sequence using a container blender CML 10 (Glatt, Germany) to ensure optimal homogeneity of the multicomponent mixture. The resulting blend was compressed into tablets with a diameter of 17 mm and an average weight of 1500 mg using a rotary tablet press XL 100 (Korsch, Germany), with compression forces ranging from 10 kN to 25 kN. The finished effervescent tablets were then packed into blisters using a Fantasy blister machine (Fantasy Standard OMAR S.r.l., Italy) to provide a robust barrier against environmental factors, ensuring the stability of the moisture-sensitive formulation. Pharmaco-technological and phisico-chemical properties To evaluate the pharmaco-technological properties of the powders, the tableting blend was tested for bulk density, tapped density, and Carr's index using a tapped density tester SVM 202 (ERWEKA GmbH, Germany). Flowability and the angle of repose were determined using a flow tester GTB (ERWEKA GmbH, Germany). According to the established gradation, a Carr's index value in the range of 12%-16% corresponds to good flowability, 18%-21% to fair/passable, and 23%-35% to poor flowability [8,15,22]. Flowability and the angle of repose were expressed as the average of three independent measurements [22]. A complex indicator on a five-point scale, accounting for matrix filling uniformity, adhesion (sticking), and extrusion force, was utilized to evaluate the compression process. The finished effervescent tablets were characterized by appearance, mass uniformity, hardness, friability, and disintegration time. The appearance was determined visually in daylight on a white background, assessing the surface integrity, smoothness, glossiness, and edge evenness. These attributes, along with the presence of inclusions, were rated on a five-point scale. Quality attributes were studied using an analytical balance AB54-S (Mettler Toledo, Switzerland), a tablet hardness tester Easy Check Pro (ERWEKA GmbH, Germany), and a friability tester TAR 200 (ERWEKA GmbH, Germany). All pharmaco-technological evaluations were performed in accordance with pharmacopoeial requirements [22]. Disintegration was defined as the time until the cessation of effervescence (absence of fizzing) in a beaker containing 200 ml of water at (20 ± 2) °C [22]. The target pharmacopoeial limits were: mass uniformity ≤ ±5%, hardness ≥50 N (for 17 mm diameter), friability ≤1%, and disintegration ≤5 min [22]. Organoleptic evaluation of the resulting solution was conducted using a five-point scoring system for transparency, odor, and taste. A score of 5 points was assigned for a perfectly clear solution with a distinct pleasant aroma and a harmonious sweet-sour taste. A score of 4 points indicated slight opalescence and an acceptable taste with a faint medicinal aftertaste. Lower scores (3 to 1 points) characterized increasing turbidity, medicinal or repulsive odors, and pronounced bitterness or heavy precipitation, rendering the solution unsuitable for use. For the stability study, the tablets were subjected to long-term storage conditions at (25 ± 2) °C and (60 ± 5) % relative humidity [23]. The physico-chemical attributes of the optimized formulation, including related substances (degradation products), uniformity of dosage units, and API assay, were determined using High-Performance Liquid Chromatography on an Agilent 1260 Infinity system (Agilent Technologies, USA). For the simultaneous determination of ASA, paracetamol, and their primary degradation products – salicylic acid and 4-aminophenol, as well as other and total impurities – crushed tablets were dissolved in a mixture of water and acetonitrile (80:20 v/v). The analysis was performed using a Mediterranea SEA18 column (4.6 × 250 mm, 5 μm). The mobile phase consisted of a buffer solution (pH 3.0) and acetonitrile (80:20 v/v) at a flow rate of 1.0 ml/min. Detection was performed at 225 nm with an injection volume of 10 μl and a total run time of 20 min. For the determination of ascorbic acid, detection was conducted at 210 nm using a SphereClone NH2 column (4.6 × 250 mm, 5 μm). The mobile phase was adjusted to a phosphate buffer–acetonitrile mixture (35:65 v/v). The uniformity of dosage units was assessed according to pharmacopoeial requirements [22] via the direct High-Performance Liquid Chromatography method under the same chromatographic conditions as the API assay [24]. For the stability study, tablets were stored under long-term conditions at (25 ± 2) °C and (60 ± 5) % RH for 24 months. Samples were analyzed every 3 months in the first year and every 6 months in the second year for all CQAs mentioned above [23]. Results and discussion Qualitative composition screening Comprehensive analysis of the excipient profiles in reference marketed products An analysis of registered products with identical active ingredient dosages (300 mg ASA, 200 mg paracetamol, and 300 mg ascorbic acid), such as Afebryl®, Isofebril® vitamine C, Gripрal + C ratiopharm®, Neo-Nisidina® C, and Thomapyrin® mit Ascorbinsäure, revealed that a high-quality effervescent form requires a balanced combination of specific functional groups. Specifically, Afebryl® (Laboratórios Azevedos – Indústria Farmacêutica, S.A.) contains sodium carbonate, anhydrous citric acid, 83 mg of sorbitol, 94 mg of lactose monohydrate, sodium saccharin, lemon essence, and 8 mg of povidone. Isofebril® vitamine C (Plus Pharmacie SA) includes sodium carbonate, citric acid, lactose, sodium saccharin, lemon essential oil powder, sorbitol, and 8 mg of povidone. Gripрal + C ratiopharm® (Ratiopharm) utilizes sodium carbonate, citric acid, sorbitol, Povidone® K25, lactose monohydrate, lemon oil, and sodium saccharin. Neo-Nisidina® C (Boehringer Ingelheim Italia s.p.a.) is formulated with sodium carbonate, citric acid, lactose, lemon flavoring, sodium saccharin, polyvinylpyrrolidone, and fumaric acid. Thomapyrin® mit Ascorbinsäure (Boehringer Ingelheim RCV GmbH & Co KG) contains 200 mg of lactose monohydrate, 1550 mg of sodium carbonate, 2.6 mg of fructose, sodium saccharin, citric acid, Povidone® K25, fumaric acid, and lemon flavoring. It was established that these industrial formulations typically consist of a gas-forming mixture (such as 1550 mg of sodium carbonate with citric or fumaric acid), fillers (94-200 mg of lactose monohydrate, 83 mg of sorbitol, or 2.6 mg of fructose), disintegrants or binding agents (Povidone® K25, polyvinylpyrrolidone), sodium saccharin, and lemon flavoring. In this study, the choice of sodium bicarbonate and anhydrous citric acid as the primary gas-forming couple was based on their dominant use in these analogs and their ability to provide the optimal intensity of carbon dioxide release. The prioritized use of anhydrous forms was necessitated by the need to minimize moisture content within the tablet matrix to prevent premature autocatalytic reactions. Evaluation of the influence of excipient nature on the CQAs of the tableting blend, effervescent tablets, and resulting solution using dispersion analysis At the first stage of research, the influence of excipients from the groups of fillers, disintegrants, and lubricants on the quality indicators of the tableting blend, effervescent tablets, and solution was investigated. The selection of these specific excipients was strategically guided by their established suitability for direct compression and their chemical compatibility with effervescent matrices, derived from the market analysis described above. To systematically evaluate the impact of different chemical structures, each group included three excipients of diverse nature. The fillers (factor A), such as anhydrous lactose and sorbitol, were selected based on their prevalence in commercial analogs (such as Afebryl® and Thomapyrin®) and their specialized grades for direct compression, ensuring high water solubility, low hygroscopicity, and superior compressibility. Fructose, which is found in Thomapyrin® but is rarely used in effervescent tablets, was substituted with mannitol as a more chemically stable and versatile choice for modern effervescent matrices. For disintegrants (factor B), Povidone® K25 was chosen as a benchmark due to its presence in market formulations, where it functions not only as a binder but also as a soluble disintegrant that contributes to masking the medicinal taste of APIs. To enhance the disintegration process, it was evaluated alongside modern superdisintegrants with different functional mechanisms: crospovidone and sodium croscarmellose. Crospovidone provides rapid wicking (capillary action) without significant swelling, which is beneficial for maintaining the structural integrity of the effervescent matrix during gas evolution, while sodium croscarmellose offers high swelling capacity to accelerate tablet breakup. This combination allowed for a comparative analysis of how varying disintegration kinetics affect the dissolution rate of the multi-component ASA-paracetamol-ascorbic acid system. Regarding lubricants (factor C), the selection was strictly limited to hydrophilic or water-soluble substances commonly used in the manufacture of effervescent tablets. Sodium lauryl sulfate, sodium stearyl fumarate, and PEG 6000 were selected as technically compatible alternatives that ensure a clear and palatable solution. This systematic selection, based on the QbD approach, allowed for the construction of a robust 3x3 Greco-Latin square experimental design, ensuring that each factor level was scientifically justified by prior knowledge and the technological requirements of the dosage form. A mixture of 159 mg (10.6%) sodium bicarbonate and 135 mg (9.0%) anhydrous citric acid was used as the gas-forming mixture. The list of factors studied is given in Table 1, while the three-factor plan and the study results are presented in Table 2. Table 1Studied excipients during the qualitative composition development of effervescent tablets with acetylsalicylic acid, paracetamol, and ascorbic acid.Table 1FactorFactor levelQuantity, mg per tabletА – fillera1 – anhydrous lactose (SuperTab®22AN)a2 – sorbitol (Neosorb®P60W)a3 – mannitol (Perlitol®300DC)345В – disintegrantb1 – polyvinylpyrrolidone (Povidone®K25)b2 – crospovidone (Polyplasdone®XL-10)b3 – sodium croscarmellose45С – lubricantc1 – sodium lauryl sulfatec2 – sodium stearyl fumarate (Pruv®)c3 – PEG 600015 Studied excipients during the qualitative composition development of effervescent tablets with acetylsalicylic acid, paracetamol, and ascorbic acid. Table 2Three-factor plan of the experiment based on the 3x3 Greek-Latin square and study results of the tableting blend, effervescent tablets and solution with acetylsalicylic acid, paracetamol, and ascorbic acid.Table 2BatchАВСy1y1'y2y2'y3y3'y4y4'y5y5'y6y6'y7y7'y8y8'y9y9'y10y10'y11y11'y12y12'1а1b1с10.75170.73930.93960.920420.0019.6816.416.037.936.834434.054.781.911.9155683.113.42542а1b2с20.76780.76780.98480.963822.0320.3417.122.437.739.944442.432.0614.8314.8330550.310.54333а1b3с30.77930.76610.98260.961720.6920.3416.417.737.739.045454.264.773.793.79961020.561.04334а2b1с20.76780.78100.92450.943816.9517.2517.316.238.639.523434.644.480.890.8954591.572.08435а2b2с30.74750.73550.97020.950022.9522.5817.419.838.237.033544.012.980.790.791001221.061.04336а2b3с10.72900.71750.92240.922420.9722.2118.016.039.035.123445.275.465.265.2659331.462.29347а3b1с30.74330.75590.91020.929218.3418.6518.314.936.536.345343.242.089.2128.9664382.092.17338а3b2с20.73230.74430.90800.926519.3519.6718.025.537.738.232224.374.2512.6812.6824840.280.42449а3b3с10.74260.73060.92450.906019.6819.3615.817.136.437.343323.843.017.507.5051311.291.3833Notes: у1, у1′ – bulk density of the first and second repetitions, g/ml; у2, у2′ – tapped density of the first and second repetitions, g/ml; у3, у3′ – Carr's index of the first and second repetitions, %; у4, у4′ – flowability of the first and second repetitions, s/100 g; у5, у5′ – angle of repose of the first and second repetitions, °; у6, у6′ – pressing process of the first and second repetitions, scale; у7, у7′ – appearance of the first and second repetitions, scale; у8, у8′ – mass uniformity of the first and second repetitions, ±%; у9, у9′ – friability of the first and second repetitions, %; y10, у10′ – hardness of the first and second repetitions, N; у11, у11′ – disintegration of the first and second repetitions, min; у12, у12′ – solution transparency of the first and second repetitions, scale. Three-factor plan of the experiment based on the 3x3 Greek-Latin square and study results of the tableting blend, effervescent tablets and solution with acetylsalicylic acid, paracetamol, and ascorbic acid. Notes: у1, у1′ – bulk density of the first and second repetitions, g/ml; у2, у2′ – tapped density of the first and second repetitions, g/ml; у3, у3′ – Carr's index of the first and second repetitions, %; у4, у4′ – flowability of the first and second repetitions, s/100 g; у5, у5′ – angle of repose of the first and second repetitions, °; у6, у6′ – pressing process of the first and second repetitions, scale; у7, у7′ – appearance of the first and second repetitions, scale; у8, у8′ – mass uniformity of the first and second repetitions, ±%; у9, у9′ – friability of the first and second repetitions, %; y10, у10′ – hardness of the first and second repetitions, N; у11, у11′ – disintegration of the first and second repetitions, min; у12, у12′ – solution transparency of the first and second repetitions, scale. The results of the statistical processing using dispersion analysis are provided in the supplementary materials (Table A). The analysis of the bulk density (y1) data demonstrated the advantages of sodium stearyl fumarate (0.7596 g/ml) and SuperTab® 22AN (0.7620 g/ml) over the other studied excipients. Regarding the tapped density (y2), SuperTab® 22AN (0.9588 g/ml), PEG 6000 (0.9507 g/ml), and Polyplasdone® XL-10 (0.9506 g/ml) exhibited the most favorable properties. The Carr's index (y3) was most significantly influenced by Povidone® K25 (18.48%), Perlitol® 300DC (19.18%), and sodium stearyl fumarate (19.27%). The dispersion analysis for flowability (y4) and the angle of repose (y5) showed that all studied factors were statistically insignificant, as Fexperimental < F0.05. However, the significance of factors A and C was established when evaluating the pressing process (y6) and the tablet appearance (y7), where SuperTab® 22AN and PEG 6000 showed significant advantages. Sodium stearyl fumarate exerted a dominant effect on mass uniformity (y8), ensuring a deviation of ±3.41%, followed by Polyplasdone® XL-10 (±3.35%) and Perlitol® 300DC (±3.47%). The lowest tablet friability (y9) was achieved using Neosorb® P60W. Tablet hardness (y10) was primarily influenced by the nature of the lubricants, with PEG 6000 yielding a hardness of 87 N. Dispersion analysis also identified Polyplasdone® XL-10 (0.61 min) and sodium stearyl fumarate (1.20 min) as the leading excipients for the disintegration time (y11) of the ASA, paracetamol, and ascorbic acid effervescent tablets. Finally, the experimental results confirmed that sodium lauryl sulfate produces the most transparent solution (y12) upon dissolution. Identification and selection of the optimal qualitative matrix (fillers, disintegrants, and lubricants) The dispersion analysis of the experimental data concluded that the optimal qualitative matrix for most pharmaco-technological properties consists of SuperTab® 22AN, Polyplasdone® XL-10, and Pruv® (sodium stearyl fumarate). Quantitative composition development Determination of the stoichiometric ratio for the gas-forming mixture (citric acid/sodium bicarbonate) The selection of an optimal ratio for the gas-forming mixture is a critical stage in the formulation of effervescent tablets. In the initial experimental batches (1-9), a mixture of 135 mg (9.0%) anhydrous citric acid and 159 mg (10.6%) sodium bicarbonate was utilized, representing a mass ratio of 1:1.178. While this combination ensured compliance with pharmacopoeial disintegration standards (ranging from 0.28 to 3.42 min), it was primarily empirical and required further refinement to ensure chemical efficiency. To achieve a scientifically justified balance and ensure a complete chemical reaction without unreacted residues, a stoichiometric calculation was performed. Based on the molar masses of anhydrous citric acid (C6H8O7, 192.123 g/mol) and sodium bicarbonate (NaHCO3, 84.01 g/mol), the interaction follows the equation: 3NaHCO3+ HOC-CH3-CH3-(COOH)3 = HOC-CH3-CH3-(COONa)3+ 3H2O + 3CO2. According to this stoichiometry, 192.123 g of C6H8O7 reacts equivalently with 252.03 g of NaHCO3 (3х84.01 g), yielding a precise mass ratio of 1:1.312. This theoretically justified ratio was subsequently implemented in all following experimental series to maximize effervescence efficiency and ensure the pH stability of the resulting solution. The transition from the 1:1.178 ratio to the stoichiometric 1:1.312 ratio allowed for a more controlled and reproducible disintegration process. Investigation of the quantitative characteristics of excipients and their interrelationships using regression analysis In order to study the quantitative characteristics and the relationship between the other excipients, four factors at five levels were studied, the list of which is provided in Table 3. To obtain tablets with an average weight of 1500 mg, the required quantity of SuperTab® 22AN was added to each batch. The experimental design matrix and the results of the study of powder mixtures and tablets are shown in Table 4. Table 3Quantitative factors and experimental levels per tablet.Table 3FactorFactor levelLower “star” point (–α)Lower (−)Basic (0)Upper (+)Upper “star” point (+α)х1 – quantity of anhydrous citric acid, mg105.0120.0135.0150.0165.0х2 – quantity of sodium bicarbonate, mg135.0157.5180.0202.5225.0х3 – quantity of Polyplasdone®XL-10, mg30.037.545.052.560.0х4 – quantity of Pruv®, mg22.530.037.545.052.5 Quantitative factors and experimental levels per tablet. Table 4Experimental design matrix and results for the quantitative optimization of the effervescent tablet formulation.Table 4Batchх1х2х3х4у1у2у3у4у5у6у7у8у9у10у1110++++0.77410.997822.4113.836.9541.2724.002.894811-+++0.71270.976126.9817.737.3540.8131.677.642912+-++0.75000.974023.0017.135.7542.0633.678.343013--++0.72420.986826.6116.836.6440.9132.336.603114++-+0.78771.020522.8117.437.4442.0940.675.822815-+-+0.75760.993323.7315.039.1541.4432.674.964316+--+0.76270.989022.8815.439.0541.3941.003.954917---+0.74790.980423.7117.137.4541.2836.334.603118+++-0.75000.982523.6720.637.2551.3228.008.234219-++-0.73770.974024.2616.835.3550.8320.679.473020+-+-0.72580.971925.3217.936.9450.8512.339.004521--+-0.72580.953423.8720.338.4551.1527.678.892722++--0.75000.989024.1718.837.0541.1122.009.353323-+--0.72740.974125.3216.637.6441.3123.338.333524+---0.72580.941422.9017.038.3451.1223.005.632425----0.75000.965722.3320.234.5440.7534.674.742626+α0000.76270.991223.0519.435.0550.8133.673.633527-α0000.77240.973920.6915.935.7541.0137.333.8828280+α000.72740.980425.8116.737.5540.8831.003.8537290-α000.72900.961724.1916.737.7541.5134.672.91343000+α00.74380.957422.3116.836.6541.5029.674.29353100-α00.76270.989022.8816.836.5541.4149.002.642732000+α0.73770.978324.5918.138.7541.2529.675.412233000-α0.71590.959625.4018.237.8551.3425.004.98253400000.73770.967723.7716.535.6451.4032.673.67243500000.73930.959622.9517.737.2541.2444.332.91173600000.73770.957422.9516.436.5553.5149.001.12203700000.73770.978324.5916.036.5442.4252.330.3239Notes: у1 – bulk density, g/ml; у2 – tapped density, g/ml; у3 – Carr's index, %; у4 – flowability, s/100 3g; у5 – angle of repose, °; у6 – pressing process, score; у7 – appearance, score; у8 – mass uniformity, ±%; у9 – hardness, N; у10 – friability, %; у11 – disintegration, s. Experimental design matrix and results for the quantitative optimization of the effervescent tablet formulation. Notes: у1 – bulk density, g/ml; у2 – tapped density, g/ml; у3 – Carr's index, %; у4 – flowability, s/100 3g; у5 – angle of repose, °; у6 – pressing process, score; у7 – appearance, score; у8 – mass uniformity, ±%; у9 – hardness, N; у10 – friability, %; у11 – disintegration, s. The relationships between the studied quantitative factors and the pharmaco-technological properties of the powder blends and effervescent tablets were described by second-order regression equations. For bulk density (y1), Fexp. = 167.37, indicating that the regression model is inadequate for this parameter. The relationship between the factors and tapped density (y2) is described by the following equation (Fexp. = 0.71): у2= 0.9658 + 0.0076х2 + 0.0085х4. Analysis of this equation shows that at the basic level, the tapped density of the tableting blend is 0.9658 g/ml. Increasing the concentrations of sodium bicarbonate (x2) and sodium stearyl fumarate (x4) leads to an improvement in this value, while the influence of other factors remains statistically insignificant. For the Carr's index (y3), although Fexp. = 1.21, the resulting equation is у3 = 23.57. This indicates that the powder mixture exhibited poor flowability regardless of variations in the studied excipient quantities. The impact of quantitative factors on flowability (y4) is described as (Fexp. = 2.74): у4 = 16.7 – 0.8х4 + 0.7х1х2. An increase in sodium stearyl fumarate content improves this indicator. Additionally, a significant interaction between anhydrous citric acid (x1) and sodium bicarbonate (x2) was observed. The relationship with the angle of repose (y5) is expressed as (Fexp. = 1.43): у5= 36.45 + 0.50х42. The concentration of sodium stearyl fumarate has the most significant effect; specifically, its introduction at the lower “star” point level reduces the angle of repose. All experimental batches demonstrated good compressibility, with a mean rating of 4.5 points (Fexp. = 0.49). Variations in excipient quantities did not statistically affect the compression process (y6) or the tablet appearance (y7), which remained consistent at 4.5 points (Fexp. = 0.20). Mass uniformity (y8) is described by the following equation (Fexp. = 5.14): у8= 1.39 + 0.10х1 + 0.11х4 + 0.13х1х4 – 0.13х2х3 – 0.12х12. The most significant impact on this attribute is exerted by the interactions between sodium bicarbonate (x2) and Polyplasdone® XL-10 (x3), as well as between citric acid (x1) and sodium stearyl fumarate (x4). While adding citric acid at 150 mg per tablet initially decreases uniformity, reaching the upper “star” point improves it. Notably, mass uniformity did not exceed ±2% in any experimental series. The hardness (y9) of the tablets is described by (Fexp. = 4.12): у9 = 44.25 – 2.63х2 – 3.38х3 + 4.21х4 + 2.44х1х2 – 1.98х22 – 3.98х42. As shown in the univariate dependence (Fig. 1), the effect of sodium stearyl fumarate (x4) is parabolic, reaching maximum hardness at x4= +0.5. Hardness also increases as Polyplasdone® XL-10 content decreases to 2.5%. The interaction of the gas-forming mixture components further enhances mechanical strength. The friability index (y10) was the decisive factor in selecting the optimal excipient quantities (Fexp. = 1,15): у10= 2.00 + 1.27х42 Incorporating 22.5 mg or 30 mg of sodium stearyl fumarate significantly reduces friability to within pharmacopoeial limits. Finally, disintegration (y11) is governed by (Fexp. = 1,06): у11= 23 + 4х22 (seconds). Sodium bicarbonate (x2) has a decisive influence; while increasing the content to 225 mg slightly extends the disintegration time, all tablets disintegrated within 1 min. Effect of sodium stearyl fumarate quantity on the hardness of tablets containing ASA, paracetamol, and ascorbic acid. Fig. 2A shows the contour plots for factors (x3) and (x4), with factors (x1) and (x2) stabilized at the basic level. To meet pharmacopoeial requirements, the optimal ratio of (x3) and (x4) was determined using response surface analysis. Hardness (y9) and friability (y10) were identified as the most significant optimization parameters for determining the quantities of crospovidone and sodium stearyl fumarate. It was established that stabilizing (x3) at the lower “star” point (-α) ensures the highest tablet strength (y8, y9). It is advisable to maintain factor (x4) at the basic level to ensure minimum friability (у10), higher hardness (у9), and better flow properties (у2, у4, у5). To identify the optimal excipient concentrations, the regression equation was transformed into an expression with two variables by replacing (x3) with (−2) (since (b3) is negative) and setting (x4 = 0). New models were then constructed. Since the quantities of citric acid and sodium bicarbonate do not significantly affect the angle of repose or tablet friability, the contour plots in the (x1x2) coordinate system were constructed based on regression equations for bulk density, flowability, mass uniformity, hardness, and disintegration (Fig. 2B). Analysis of the figure indicates that optimal indicators for the effervescent tablets are achieved at (x1 = -α) and (x2 = −1.2). Contour plots (equal yield lines) in (A) the х3х4 coordinate system with other factors stabilized at the basic level, and (B) the х1х2 coordinate system based on the results of the transformed regression equations. Selection of excipient concentrations that ensure superior pharmaco-technological properties As a result of the experimental series, the following excipient quantities providing the optimal pharmaco-technological indicators for the tableting blend and effervescent tablets were selected: 105 mg of anhydrous citric acid, 153 mg of sodium bicarbonate, 30 mg of Polyplasdone® XL-10, and 37.5 mg of Pruv®. The resulting tableting blend was characterized by a bulk density of 0.7258 g/ml, tapped density of 0.95668 g/ml, Carr's index of 24.13%, flowability of 18.4 s/100 g, and an angle of repose of 36.45°. The mixture exhibited good compressibility, and the appearance of the effervescent tablets was rated at 4 points. The obtained tablets demonstrated a mass uniformity of ±0.41%, hardness of 57.17 N, and a rapid disintegration time of 28 s. However, the friability (2.0%) exceeded pharmacopoeial limits, and the resulting solution was cloudy with visible suspensions, possessing an unpleasant bitter taste. Formulation optimization Analysis of additional excipients to enhance the technological and organoleptic properties (glidants, sweeteners, and flavorings) via dispersion analysis To further optimize the tableting blend and enhance the consumer attributes of the effervescent tablets, the next stage of research focused on flowability and organoleptic properties. To improve the fluidity of the multicomponent mixture and prevent the adhesion of granules to the punch surfaces, three glidants (factor A) were investigated: colloidal anhydrous silicon dioxide (а1 – Aerosil® 200 and а2 – Aeroperl® 300) and а3 – magnesium aluminosilicate (Neuselin® US2). These excipients were selected for their high specific surface area and their ability to minimize interparticulate friction, which is critical for maintaining a stable flow during the direct compression of hygroscopic effervescent components. To effectively mask the characteristic bitter taste of paracetamol and ASA, the formulation was supplemented with sweeteners (factor B) and flavorings (factor C), based on the organoleptic profiles of market analogs (e.g., Afebryl®, Thomapyrin®). Sodium saccharin (b1) and aspartame (b2) were selected as high-intensity sweeteners, while b3 – dextrose (Compri-Zuger® B) was included as a multifunctional agent providing both sweetness and structural bulk for direct compression. The choice of flavorings (с1 – lemon, с2 – orange, and с3 – lemon-lime) was guided by their superior ability to complement the natural acidity of the effervescent base, providing a pleasant sensory experience upon dissolution. Based on the preliminary results, which showed rapid disintegration within 1 min, the quantity of the superdisintegrant Polyplasdone® XL-10 was adjusted to 8 mg per tablet to balance the disintegration rate with the mechanical strength of the tablet. To achieve a target average weight of 1500 mg, varying quantities of Compri-Zuger®B were added to each batch as a bulking agent. These factors were organized into a robust 3x3 Greek-Latin square experimental plan, the results of which are presented in Table 5. Table 5Experimental design matrix and characterization of the tableting blend, effervescent tablets, and resulting solution during the formulation optimization stage.Table 5BatchАВСy1y1'y2y2'y3y3'y4y4'y5y5'y6y6'y7y7'y8y8'y9y9'y10y10'y11y11'y12y12'y13y13'y14y14'38а1b1с10.72800.73600.95690.962423.9223.5211.813.143.943.854440.690.6934391.491.451.011.1645345439а1b2с20.71530.72340.93300.941223.3323.1414.816.142.842.455440.710.6333391.971.951.121.1044553340а1b3с30.71330.72850.95110.938125.0022.3414.214.344.245.154440.630.6830361.961.901.571.5634553441а2b1с20.74000.74811.00120.995326.0924.8414.717.943.644.154440.970.8323273.163.101.531.5534555442а2b2с30.74300.75100.96460.970022.9722.5817.515.444.544.654450.920.9123262.642.601.272.0643453343а2b3с10.75000.75760.98680.992124.0023.6412.813.144.244.654551.511.2337421.161.152.263.4344443444а3b1с30.69730.69030.94920.943926.5426.8714.417.744.944.054551.481.5739461.111.105.204.3444445445а3b2с10.66790.68240.91780.923227.2326.0814.617.045.144.955551.031.1236451.081.052.503.2454454346а3b3с20.67100.65730.92030.907327.0927.5517.417.945.243.654551.441.4250550.570.553.403.44344434Notes: у1, у1′ – bulk density of the first and second repetitions, g/ml; у2, у2′ – tapped density of the first and second repetitions, g/ml; у3, у3′ – Carr's index of the first and second repetitions, %; у4, у4′ – flowability of the first and second repetitions, s/100 g; у5, у5′ – angle of repose of the first and second repetitions, °; у6, у6′ – pressing process of the first and second repetitions, scale; у7, у7′ – appearance of the first and second repetitions, scale; у8, у8′ – mass uniformity of the first and second repetitions, ±%; y9, y9′ – hardness of the first and second repetitions, N; y10, y10′ – friability of the first and second repetitions, %; y11, y11' – disintegration of the first and second repetitions, min; у12, у12′ – solution transparency of the first and second repetitions, scale; y13, y13′ – solution odor of the first and second repetitions, scale; y14, y14′ – solution taste of the first and second repetitions, scale. Experimental design matrix and characterization of the tableting blend, effervescent tablets, and resulting solution during the formulation optimization stage. Notes: у1, у1′ – bulk density of the first and second repetitions, g/ml; у2, у2′ – tapped density of the first and second repetitions, g/ml; у3, у3′ – Carr's index of the first and second repetitions, %; у4, у4′ – flowability of the first and second repetitions, s/100 g; у5, у5′ – angle of repose of the first and second repetitions, °; у6, у6′ – pressing process of the first and second repetitions, scale; у7, у7′ – appearance of the first and second repetitions, scale; у8, у8′ – mass uniformity of the first and second repetitions, ±%; y9, y9′ – hardness of the first and second repetitions, N; y10, y10′ – friability of the first and second repetitions, %; y11, y11' – disintegration of the first and second repetitions, min; у12, у12′ – solution transparency of the first and second repetitions, scale; y13, y13′ – solution odor of the first and second repetitions, scale; y14, y14′ – solution taste of the first and second repetitions, scale. The results of the statistical processing of the experimental data are presented in the supplementary materials (Table B). Dispersion analysis demonstrated that factor A (glidants) significantly influenced the bulk density, tapped density, Carr's index, flowability, angle of repose, tablet appearance, mass uniformity, hardness, friability, and disintegration. The tableting blend containing Aerosil® 200 exhibited the best flowability, while the lowest friability was observed in tablets formulated with Neuselin® US2. Factor B (sweeteners) was found to be significant for tapped density, mass uniformity, hardness, friability, disintegration, and the taste of the resulting solution. Organoleptic evaluation confirmed that sodium saccharin effectively masked the unpleasant bitter taste of paracetamol, providing a pleasant sweet flavor. Based on the dispersion analysis, factor C (flavorings) played a crucial role in determining the bulk density, flowability, angle of repose, friability, and solution odor. Lemon flavoring showed a distinct advantage regarding its impact on tablet friability, while orange flavoring provided the most persistent and specific solution odor. Selection of the best functional components using a utility function The utility function was employed to identify the optimal excipients among the studied glidants, sweeteners, and flavorings (Table 6). The experimental data indicate that colloidal anhydrous silicon dioxide (Aerosil® 200, factor a1), sodium saccharin (b1), and lemon flavoring (c1) yielded the highest overall quality indicators for the tableting blend, effervescent tablets, and resulting solution. Table 6Summary of ranked series of advantages for excipient selection.Table 6Quality indicatorFactor levelа1а2а3b1b2b3с1с2с3Bulk density213---1.531.5Tapped density213132---Carr's index123------Flowability123---132Angle of repose321---231Pressing process---------Appearance321------Mass uniformity123213---Hardness231231---Friability231123123Disintegration123213---Solution transparency---------Solution odor------312Solution taste---132---Sum1820221113128.5129.5 Summary of ranked series of advantages for excipient selection. Assessment of Aerosil® 200 concentration impact on powder flow and tablet quality To optimize the formulation, the influence of varying concentrations of Aerosil® 200 was investigated. The pharmaco-technological indicators of the tableting blend, tablets, and resulting solution are presented in Table 7. Experimental data confirm that the introduction of Aerosil® 200 reduces both the bulk density (y1) and tapped density (y2), which consequently leads to a deterioration in the flow properties of the powders. This is evidenced by an increase in the flow time (y4), a critical parameter for the compression process. While an increase in Aerosil® 200 concentration slightly improved mass uniformity (y8), mechanical strength (y9, y10), and disintegration rate (y11), these improvements were marginal. Given the negative impact on the flowability of the multicomponent mixture, it was decided not to include Aerosil® 200 in the final composition of the effervescent tablets. Table 7Effect of Aerosil® 200 quantity on the pharmaco-technological parameters of the tableting blend, effervescent tablets, and resulting solution containing acetylsalicylic acid, paracetamol, and ascorbic acid.Table 7BatchQuantity of Aerosil®200, %y1y2y3y4y5y6y7y8y9y10y11y12y13y14470.000.72150.980026.3812.244.0550.41322.192.08555480.250.71350.925722.9214.342.8450.33372.012.53544490.500.72800.956923.9213.143.9440.69392.491.16545500.750.68500.939427.0816.442.1450.47431.541.56545511.000.67710.873222.4614.943.5550.79441.051.14555Notes: у1 – bulk density, g/ml; у2 – tapped density, g/ml; у3 – Carr's index, %; у4 – flowability, s/100 3g; у5 – angle of repose, °; у6 – pressing process, score; у7 – appearance, score; у8 – mass uniformity, ±%; у9 – hardness, N; у10 – friability, %; у11 – disintegration, min; y12 – solution transparency, scale; y13 – solution odor, scale; y14 – solution taste, scale. Effect of Aerosil® 200 quantity on the pharmaco-technological parameters of the tableting blend, effervescent tablets, and resulting solution containing acetylsalicylic acid, paracetamol, and ascorbic acid. Notes: у1 – bulk density, g/ml; у2 – tapped density, g/ml; у3 – Carr's index, %; у4 – flowability, s/100 3g; у5 – angle of repose, °; у6 – pressing process, score; у7 – appearance, score; у8 – mass uniformity, ±%; у9 – hardness, N; у10 – friability, %; у11 – disintegration, min; y12 – solution transparency, scale; y13 – solution odor, scale; y14 – solution taste, scale. Research of fillers nature To enhance the mechanical hardness of the effervescent tablets, various fillers based on dextrose (batches 52–54), sorbitol (batch 55), and microcrystalline cellulose (batch 56) were evaluated. The study results are summarized in Table 8. The data indicate the superiority of Parteck® SI400 (sorbitol-based) in terms of Carr's index (y3), angle of repose (y5), and hardness (y9). It was also noted that bulk density (y1), tapped density (y2), flowability (y4), and friability (y8) improved when using sugar spheres (Scerinerts® 50). Batch 53, containing Compri-Zuger® G, exhibited the best flowability (y4) and mass uniformity (y6). However, despite these advantages, none of the investigated fillers independently ensured sufficient tablet hardness to meet pharmacopoeial requirements. Table 8Pharmaco-technological properties of the tableting blend and effervescent tablets based on various filler types.Table 8BatchFillery1y2y3y4y5y6y7y8y952Compri-Zuger®M3 (dextrose)0.73750.997226.0414.642.20.6949.7520.0053Compri-Zuger®O (dextrose)0.73010.976925.2611.444.20.5349.8618.3354Scerinerts®50 (sugar spheres)0.78591.067526.3811.942.50.8722.9611.3355Parteck®SI400 (sorbitol)0.70520.933724.4713.443.80.7637.4322.3356Cellets®100 (micropellets of microcrystalline cellulose)0.77871.065626.9212.741.71.00110.264.00Notes: у1 – bulk density, g/ml; у2 – tapped density, g/ml; у3 – Carr's index, %; у4 – flowability, s/100 3g; у5 – angle of repose, °; y6 – mass uniformity, ±%; y7 – appearance, score; y8 – friability, %; y9 – hardness, N. Pharmaco-technological properties of the tableting blend and effervescent tablets based on various filler types. Notes: у1 – bulk density, g/ml; у2 – tapped density, g/ml; у3 – Carr's index, %; у4 – flowability, s/100 3g; у5 – angle of repose, °; y6 – mass uniformity, ±%; y7 – appearance, score; y8 – friability, %; y9 – hardness, N. Evaluation of filler-binder correlations using regression analysis To increase the mechanical hardness of the effervescent tablets, combinations of lactose and sorbitol in various ratios were studied. Parteck® SI400, which provided the highest mechanical strength, was selected for further experiments. To optimize the formulation, Ludipress® – a co-processed multifunctional excipient consisting of lactose, polyvinylpyrrolidone, and crospovidone – was investigated. Its inclusion as a specialized binder and superdisintegrant allowed for the exclusion of individual crospovidone from the formulation, thereby simplifying the manufacturing process and reducing the duration of the technological cycle. The quantitative factors and their experimental levels investigated to optimize the composition of effervescent tablets containing ASA, paracetamol, and ascorbic acid are presented in Table 9. The final formulation included 7% anhydrous citric acid, 10.2% sodium bicarbonate, 0.36% sodium saccharin, 1.8% lemon flavoring, and 1.5% sodium stearyl fumarate (Pruv®). Lactose monohydrate (Tablettose® 80) was utilized as a filler to achieve the target average tablet weight of 1500 mg. The experimental design and the corresponding results for the tableting blend, effervescent tablets, and resulting solution are summarized in Table 10. Table 9Investigated factors and their experimental levels per tablet used for the optimization of the effervescent formulation.Table 9FactorFactor levelLower “star” point (–α)Lower (−)Basic (0)Upper (+)Upper “star” point (+α)х1 – quantity of Ludipress®, mg2.465333.95110186.05217.5347х2 – quantity of Parteck®SI400, mg2.465333.95110186.05217.5347 Investigated factors and their experimental levels per tablet used for the optimization of the effervescent formulation. Table 10Experiment design and quality attributes of the tableting blend, effervescent tablets, and resulting solution containing acetylsalicylic acid, paracetamol, and ascorbic acid.Table 10Batchх1х2у1у2у3у4у5у6у7у8у9у10у11у12у13у1457++0.67360.884823.8722.839.8540.6149.22.061.0245558-+0.68960.893522.8221.040.3440.5446.42.471.2344559+-0.66320.890625.5323.541.6550.5341.03.160.2444560--0.67470.867422.2221.742.5440.8236.83.880.4344561+α00.67770.890325.0018.341.4550.7453.22.380.4144562-α00.69360.893222.3518.940.6440.4539.53.150.59455630+α0.67960.891423.7617.840.9550.5846.42.351.23455640-α0.67020.887624.4921.541.3441.0544.23.721.0844565000.67550.907125.5318.941.3550.4553.02.411.3244566000.67940.904824.9121.940.5440.5046.22.451.27455Notes: у1 – bulk density, g/ml; у2 – tapped density, g/ml; у3 – Carr's index, %; у4 – flowability, s/100 3g; у5 – angle of repose, °; у6 – pressing process, score; у7 – appearance, score; у8 – mass uniformity, ±%; у9 – hardness, N; у10 – friability, %; у11 – disintegration, min; y12 – solution transparency, scale; y13 – solution odor, scale; y14 – solution taste, scale. Experiment design and quality attributes of the tableting blend, effervescent tablets, and resulting solution containing acetylsalicylic acid, paracetamol, and ascorbic acid. Notes: у1 – bulk density, g/ml; у2 – tapped density, g/ml; у3 – Carr's index, %; у4 – flowability, s/100 3g; у5 – angle of repose, °; у6 – pressing process, score; у7 – appearance, score; у8 – mass uniformity, ±%; у9 – hardness, N; у10 – friability, %; у11 – disintegration, min; y12 – solution transparency, scale; y13 – solution odor, scale; y14 – solution taste, scale. The regression equation for bulk density (y1) of tableting blend is as follows (Fexp. = 1.73): у1 = 0.6779 – 0.0062х1 + 0.0048х2. Analysis of this equation indicates that at the basic level of the investigated factors, the bulk density was 0.6779 g/ml. This indicator decreases with the addition of Ludipress®, whereas an increase in the quantity of Parteck® SI400 leads to a higher bulk density. The relationship between the studied factors and the tapped density (y2) is described by the following second-order regression equation (Fexp. = 20.10): у2= 0.9065 + 0.0013x1+ 0.0032х2 – 0.0080 × 1 × 2 – 0.0091 × 12 – 0.0102 × 22. The analysis showed that Parteck® SI400 exerts the most significant influence. At the “star” point levels, the studied factors reduce the tapped density. Furthermore, a significant interaction between the factors was observed, which adversely affects this indicator. The Carr's index (y3) is related to the investigated factors by the following equation (Fexp. = 0.35): у3= 25.23 + 1.01х1 – 0.26х2. The results confirm that factor (x1) has the greatest influence on Carr's index, with its effect being nearly four times higher than that of factor (x2). Increased Ludipress® content worsens the index, while higher Parteck® SI400 levels improve this quality attribute. Regarding flowability (y4), the regression equation (Fexp. = 0.79): у4 = 20.4. All investigated factors showed an insignificant effect, indicating an average powder discharge rate of 20.4 s/100 g regardless of excipient concentrations. The angle of repose (y5) of the tableting blend is illustrated by (Fexp. = 1.16): у5 = 40.92 - 0.57х2. An increase in Parteck® SI400 concentration significantly reduces the angle of repose. The influence on the compression process (y6) is described by the following model (Fexp. = 0.23): у6= 4.50 + 0.43х1. Compression is enhanced by increasing Ludipress® to 186.05 mg per tablet. Similarly, tablet appearance (y7) improves with higher Ludipress® content (Fexp. = 1.14): у7= 4.75 + 0.30х1. Factor x2, interaction, and quadratic dependencies were statistically insignificant. Mass uniformity (y8) is expressed by (Fexp. = 14.51): у8= 0.48 + 0.02х1 – 0.11х2 + 0.15х22. The homogeneity of the tablets improves with higher Parteck® SI400 content. Notably, mass uniformity did not exceed ±1% at any ratio within the experimental range. Tablet hardness (y9) follows the model (Fexp. = 0.50): у9= 49.63 + 3.30х1, showing improvement with increased Ludipress®, though values remained near the lower pharmacopoeial limit. Friability (y10) is expressed by (Fexp. = 13.14): у10 = 2.43 – 0.28х1 – 0.56х2 + 0.16х12 + 0.30х22. The regression equation demonstrates that the friability of the effervescent tablets depends significantly on the quantity of excipients added. The effect of Parteck® SI400 on this indicator is twice as high as that of factor x1. Fig. 3A illustrates the effect of factor x2 on the friability of tablets containing ASA, paracetamol, and ascorbic acid. Analysis of the figure indicates that increasing the Parteck® SI400 content up to 186.05 mg per tablet leads to a decrease in abrasion. However, a further increase in the quantity of Parteck® SI400 is accompanied by a gradual increase in weight loss. The lowest friability value is observed on line 4 (x1= +1, x2= +1), while lines 1 and 2 represent the zone where friability exceeds pharmacopoeial standards. The disintegration time (y11) is correlated with the studied factors by the following second-order regression equation (Fexp. = 51.34): у11 = 1.30 – 0.08х1 + 0.22х2 – 0.42х12 – 0.09х22. The equation shows that all effervescent tablets disintegrate within 2 min. The disintegration rate is primarily dependent on the quantity of Ludipress®, with higher concentrations leading to faster disintegration. Although this indicator worsens with an increase in Parteck® SI400 content, evaluating factor x2 at the “star” points reveals a leveling of this effect. The influence of Ludipress® is further illustrated by the univariate graphical dependence in Fig. 3B. The resulting curves exhibit a parabolic shape: the disintegration time initially increases, reaching a maximum at a Ludipress® concentration of 110 mg/tablet (ranging from 42 s to 1.5 min), and subsequently improves with further increases in Ludipress® content. Regarding solution transparency (y12), all batches received a score of 4 points, indicating that the investigated factors had no significant effect on solution quality. The regression equation describing the relationship between the factors and solution odor (y13) is у13 = 4.5 (Fexp. = 0.34), suggesting no correlation with the excipient quantities. Similarly, the taste of the solution (у14) was found to be independent of the Ludipress® and Parteck® SI400 concentrations, with all batches rated at 5 points. Univariate graphical dependencies: (A) Effect of Parteck® SI400 quantity on friability; (B) Effect of Ludipress® quantity on the disintegration of effervescent tablets containing ASA, paracetamol, and ascorbic acid. Based on the obtained regression equations, contour plots (equal yield lines) were constructed in the x1x2 coordinate system (Fig. 4). Analysis of the figure shows that the highest values for bulk density (y1) and Carr's index (у3) were achieved when adding 2.4653 mg of Ludipress® and 217.5347 mg of Parteck® SI400 to the effervescent tablets. An angle of repose (у5) of 41.73° was observed when 2.4653 mg of Parteck®SI400 was used, regardless of the Ludipress® amount within the studied range. The use of 217.5347 mg of Ludipress® resulted in significant improvements in the compression process (y6), tablet appearance (y7), and hardness (y9), which were decisive factors in selecting the optimal quantities. Friability (у10) was confirmed as a critical parameter, with minimum mass loss observed at 186.05 mg of the investigated excipients. By finding the intersection of the optimal regions on the contour plots and transforming the regression equations into canonical expressions, the optimal coordinates were determined. The best quality indicators for the tableting blend and effervescent tablets are achieved at a concentration of 193.7 mg of Ludipress® (x1) and 178.4 mg of Parteck® SI400 (x2) per tablet. Consequently, these quantities were selected for the final optimized formulation. Contour plots (equal yield lines) in the х1х2 coordinate system. Final formulation and validation Experimental validation of the optimized composition Based on the multi-stage experimental design, an optimal composition for effervescent tablets was proposed, containing 300 mg of ASA, 200 mg of paracetamol, and 300 mg of ascorbic acid. The matrix also included 105 mg of anhydrous citric acid, 153 mg of sodium bicarbonate, 193.7 mg of Ludipress®, 178.4 mg of sorbitol (Parteck® SI400), 5.4 mg of sodium saccharin, 27 mg of lemon flavoring, and 37.5 mg of sodium stearyl fumarate (Pruv®). The experimental reproduction of this formulation confirmed its superior technological properties: bulk density was 0.675 g/ml, tapped density 0.880 g/ml, Carr's index 26.2%, flowability 15.3 s/100 g, and the angle of repose was 40.5°. The pressing process and the appearance of the tablets were rated at 5 points. The finished tablets demonstrated excellent mechanical and pharmacopoeial characteristics, including mass uniformity (±0.6%), hardness (53 N), friability (0.6%), and rapid disintegration (1 min 12 s). The resulting solution had a pleasant odor and a pleasant sweet-sour taste. The obtained indicators met all pharmacopoeial requirements and complied with the criteria of the Quality Target Product Profile. Long-term stability testing and final characterization of the dosage form Since ascorbic acid is an inherently unstable compound that undergoes rapid oxidation and degradation under high temperature and humidity [20], accelerated stability studies were not conducted. Instead, to determine the shelf life, the tablets were packed in blister packages manufactured from aluminum-polymer laminate foils and aluminum foil [21]. This choice of packaging is scientifically justified by the need for a high moisture and light barrier, as the multi-layer aluminum laminate (cold-form foil) provides near-zero water vapor transmission rates, protecting the hygroscopic effervescent couple and preventing the catalytic degradation of ASA and ascorbic acid. The tablets were subjected to long-term storage at (25 ± 2) °C and (60 ± 5) % relative humidity [23]. Monitoring was performed over 24 months, with sampling every 3 months in the first year and every 6 months in the second year. Critical parameters such as appearance, average weight, related substances, disintegration, uniformity of dosage units, and API assay were evaluated (Table 11). The results prove that at 25 °C, the formulation remains within the established specification limits for the entire 24-month period, confirming the absence of detrimental interactions between the APIs and excipients and ensuring the product's commercial viability. Table 11Results of a study of the stability of effervescent tablets with ASA, paracetamol and ascorbic acid under long-term storage conditions.Table 11TestSpecificationTest period (months)0369121824AppearanceWhite or almost white, flat-faced, bevelled-edge tablets with a score line, having a faint lemon odorCompliesCompliesCompliesCompliesCompliesCompliesCompliesAverage weightFrom 1425 mg to 1575 mg (1500 mg ± 5%)1501 mgNot testedNot testedNot testedNot testedNot tested1509 mgRelated substances:Salicylic acid1.0%0.10%0.12%0.15%0.17%0.20%0.26%0.39%4- aminophenol0.1%Not detectedNot detectedNot detected0.01%0.01%0.01%0.02%Any other impurity0.2%0.01%0.02%0.02%0.03%0.03%0.04%0.04%Total impurities2.0%0.11%0.15%0.19%0.21%0.25%0.32%0.47%Disintegration time≤5 min1 min 12 sNot testedNot testedNot testedNot testedNot tested1 min 07 sUniformity of dosage units:ASAAV≤15.02.5Not testedNot testedNot testedNot testedNot tested3.2Paracetamol3.13.8Ascorbic acid2.83.5Assay:ASAFrom 285 mg to 315 mg299 mg298 mg300 mg297 mg295 mg294 mg289 mgParacetamolFrom 190 mg to 210 mg201 mg205 mg204 mg202 mg202 mg198 mg196 mgAscorbic acidFrom 285 mg to 315 mg304 mg301 mg300 mg302 mg306 mg302 mg299 mg Results of a study of the stability of effervescent tablets with ASA, paracetamol and ascorbic acid under long-term storage conditions. Limitation In the present study, a stable composition and direct compression technology for effervescent tablets containing acetylsalicylic acid, paracetamol, and ascorbic acid were successfully developed. However, certain technical limitations must be considered for industrial scale-up. Specifically, for the proposed formulation, maintaining the compression force within the established range (10–25 kN) is critical. Deviations beyond these limits can significantly affect the CQAs of the final product, such as mechanical hardness and friability. Furthermore, due to the high hygroscopicity of the effervescent components, the environmental humidity during the manufacturing process must be strictly controlled to prevent premature degradation. Therefore, continuous monitoring of tablet hardness and mass uniformity is essential during the compression stage to ensure the reproducibility of the optimized formulation. Conclusion A stable and scientifically substantiated composition for effervescent tablets containing acetylsalicylic acid, paracetamol, and ascorbic acid was successfully developed and experimentally validated. Using a systematic QbD approach, including dispersion and regression analyses, the influence of the nature and concentration of various excipients on the pharmaco-technological and organoleptic characteristics of the tableting blend and finished tablets was comprehensively investigated. The optimal combination of anhydrous citric acid, sodium bicarbonate, Ludipress®, sorbitol (Parteck® SI400), sodium saccharin, lemon flavoring, and sodium stearyl fumarate (Pruv®) was justified. The resulting formulation ensures a high-quality consumer appearance, solution transparency, and pleasant taste, while strictly adhering to all pharmacopoeial requirements. The developed formulation provides a fast-acting and accessible domestic alternative for fever reduction, pain relief, and immune support, particularly for headaches, toothaches, and symptoms of flu and colds. The study demonstrated that the integrated use of statistical methods, such as the utility function and response surface methodology, provides a robust algorithm for the pharmaceutical development of complex multicomponent dosage forms. Ethics approval Not applicable. Declaration of generative AI in scientific writing No generative AI tools have been used throughout the entire writing process of this manuscript. Funding information This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments The author expresses her sincere gratitude to JSC Farmak (Kyiv, Ukraine) for providing raw materials and equipment for the study. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.pscia.2026.100123. Supplementary data The following is the Supplementary data to this article: Multimedia component 1 Data availability There is the supplementary material to this article. References Associated Data Supplementary Materials Multimedia component 1 Data Availability Statement There is the supplementary material to this article.